Disease · MONDO_0021245
oral cavity neoplasm
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. oral cavity neoplasm. Diseases, record MONDO_0021245. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021245
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Cancer of Mouth, Cancer of the Mouth, Cancer, Mouth, Cancer, Oral, Cancers, Mouth, Cancers, Oral, MOUTH NEOPL, Mouth Cancer, Mouth Cancers, Mouth Neoplasms, NEOPL MOUTH, NEOPL ORAL, Neoplasm, Mouth, Neoplasm, Oral, Neoplasms, Mouth, Neoplasms, Oral, ORAL NEOPL, Oral Cancer, Oral Cancers, Oral Neoplasm, Oral Neoplasms, mouth neoplasm, mouth tumor, mouth tumour, neoplasm of oral cavity, oral cavity neoplasm (disease), oral cavity tumor, oral cavity tumour, tumor of oral cavity, tumour of oral cavity
- Open Targets
- Highest stage of its drugs
- Phase 3, for 3 of its 22 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs22
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CONTUSUGENE LADENOVEC | CHEMBL2108585 | Gene | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
| CETUXIMAB | CHEMBL1201577 | Antibody | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AMINOLEVULINIC ACID | CHEMBL601 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| HYDROXYUREA | CHEMBL467 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METRONIDAZOLE | CHEMBL137 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 22
See all 22 drugsTargets39
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRB1 | Adrenergic receptor | 2 | Adrenergic receptor agonist; Beta-1 adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor | 2 | Adrenergic receptor agonist; Beta-2 adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/154 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 2 | Programmed cell death protein 1 inhibitor | Phase 1 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| ADRA1A | Adrenergic receptor | 1 | Adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor | 1 | Adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor | 1 | Adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRA2A | Adrenergic receptor | 1 | Adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor | 1 | Adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor | 1 | Adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/152 | Drugs and targets |
1 to 10 of 39
See all 39 targetsTrials17
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03638622 | Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer. | Phase 1/2 | 30 | 2021-02-21 | Oral Cancer | AMINOLEVULINIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT00953849 | Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity | Phase 1/2 | 21 | 2016-12-21 | Mouth Neoplasms | CALCITRIOL, CELECOXIB | Its record names the disease | ClinicalTrials.gov |
| NCT01434394 | Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer | Phase 2/3 | 243 | Locally Advanced Malignant Neoplasm, Oral Cancer, Oropharyngeal Carcinoma, Effects of Chemotherapy | CETUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00002747 | Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer | Phase 3 | 240 | Head and Neck Cancer | CISPLATIN, FLUOROURACIL | Its record names the disease | ClinicalTrials.gov | |
| NCT01440270 | Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer | Phase 2 | 145 | Locally Advanced Malignant Neoplasm, Oral Cancer, Oropharyngeal Carcinoma | CETUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06876038 | Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions | Phase 2 | 65 | Oral Cancer, Oral Cavity Cancer, Oral Leukoplakia, Oral Lichen Planus, Oral Squamous Cell Carcinoma | AMINOLEVULINIC ACID | Its record names the disease | ClinicalTrials.gov | |
| NCT05865548 | Addition of Aspirin to Standard of Care in Oral Cancer | Phase 2/3 | 60 | Oral Cancer | ASPIRIN | Its record names the disease | ClinicalTrials.gov | |
| NCT07082621 | N Acetylcystene in Treatment of Radiotherapy Induced Oral Mucositis in Oral Cancer Patients | Not applicable | 40 | Oral Mucositis | ACETYLCYSTEINE | Its record names the disease | ClinicalTrials.gov | |
| NCT07015333 | Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab | 31 | Oral Squamous Cell Carcinoma (OSCC) | CETUXIMAB, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov | ||
| NCT03288051 | Effects of Intraoperative, Goal-directed Crystalloid vs. Colloid Fluid Resuscitation on Free Flaps | Not applicable | 30 | Optimal Tissue Perfusion | DOBUTAMINE, NOREPINEPHRINE | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 17
See all 17 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0021245
GET https://conductscience.org/api/diseases/v1/MONDO_0021245/drugs?page=2